Medtronic teams with Stanford, UCSD on Parkinson's device; 3D-printed implants for complex injuries are on their way;

@FierceMedDev: Chutes & Ladders this week: Merck's Kim resigns to teach at Stanford med school. Feature | Follow @FierceMedDev

@MarkHFierce:  Quest Diagnostics improved the lower-end of its 2013 earnings expectations, but still says overall revenue will dip. Story | Follow @MarkHFierce

@MichaelGFierce: Brain implant recovers motor function by boosting neuron communication. Item | Follow @MichaelGFierce

@GalenMoore: Researchers say they've synthesized erythropoietin, a hormone used for doping. More via Nature | Follow @GalenMoore

> Medtronic ($MDT) is working with Stanford University and the University of California, San Diego to develop a deep-brain-stimulation device that treats Parkinson's disease but also monitors and records brain activity. Story (sub. req.)

> Germany's Epigenomics gained coverage from a French insurer for its test for the early detection of colorectal cancer. Story

> The Orthopeaedic Implant Company in Nevada is rolling out its new proximal humerus plate to help treat upper extremity fractures. Item

> Ireland's Aeorgen, a medical device and drug delivery company whose technology turns liquid medication into mist, won the Medical Technology Company of the Year Award 2013. Item

> Precision Extrusion, a N.Y.-based medical device contract manufacturer, is expanding. Story

> Researchers are on their way toward developing 3D-printed implants that could fix complex injuries. Item

Biotech News

@FierceBiotech: Genzyme's Lemtrada has been approved in Canada for treatment of multiple sclerosis. Release | Follow @FierceBiotech

@JohnCFierce: Trending: Why did Roche kill off its Alzheimer's program for the BACE inhibitor RG7129? Editor's corner | Follow @JohnCFierce

@DamianFierce: AVEO says tivozanib's colorectal cancer data isn't looking good, taking another ~15% off its already ailing shares. Story | Follow @DamianFierce

@EmilyMFierce: Report: Life science research needs standards to curb irreproducible studies. Story from FierceBiotech Research | Follow @EmilyMFierce

> Merck's allergy pill clears an FDA hurdle, but efficacy questions linger. Story

> FDA panel smiles on Bristol-Myers, AstraZeneca's diabetes drug in do-over. More

> AstraZeneca gets some good news for its late-stage gout therapy. Article

> Bill would fast-track promising antibiotics for FDA approval. News

> AbbVie's veliparib wows in a breast cancer study. Item

Pharma News

@FiercePharma: Trending now: Think Fast: New cognition study could add $350M to Lundbeck's Brintellix sales. Yesterday's story | Follow @FiercePharma

@EricPFierce: Merck KGaA sees upside in allergy meds, emerging markets. New plant to make allergy meds 4 emerging markets. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Good news for Vivus: Sanofi has signed on to sell ED drug Stendra in emerging markets. Release | Follow @CarlyHFierce

> Torrent buys Elder's domestic business, keeping it Indian controlled. Report

> 300 Novartis workers to be sacked when Alcon plant closes next year. News

> Sanofi signs on to sell Vivus ED drug in emerging markets. Story

> Emergent BioSolutions expanding with $222M deal to buy Cangene. More